Search Results - "Shepherd, Stacie"

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer by Hurley, Rachel M., Wahner Hendrickson, Andrea E., Visscher, Daniel W., Ansell, Peter, Harrell, Maria I., Wagner, Jill M., Negron, Vivian, Goergen, Krista M., Maurer, Matthew J., Oberg, Ann L., Meng, X. Wei, Flatten, Karen S., De Jonge, Maja J.A., Van Herpen, Carla D., Gietema, Jourik A., Koornstra, Rutger H.T., Jager, Agnes, den Hollander, Martha W., Dudley, Matthew, Shepherd, Stacie P., Swisher, Elizabeth M., Kaufmann, Scott H.

“…Poly(ADP-ribose) polymerase (PARP) inhibitors have shown substantial activity in homologous recombination- (HR-) deficient ovarian cancer and are undergoing…”
Get full text

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer by Manzo, Julia, Puhalla, Shannon, Pahuja, Shalu, Ding, Fei, Lin, Yan, Appleman, Leonard, Tawbi, Hussein, Stoller, Ronald, Lee, James J., Diergaarde, Brenda, Kiesel, Brian F., Yu, Jing, Tan, Antoinette R., Belani, Chandra P., Chew, Helen, Garcia, Agustin A., Morgan, Robert J., Wahner Hendrickson, Andrea E., Visscher, Daniel W., Hurley, Rachel M., Kaufmann, Scott H., Swisher, Elizabeth M., Oesterreich, Steffi, Katz, Tiffany, Ji, Jiuping, Zhang, Yiping, Parchment, Ralph E., Chen, Alice, Duan, Wenrui, Giranda, Vincent, Shepherd, Stacie P., Ivy, S. Percy, Chu, Edward, Beumer, Jan H.

“…Purpose BRCA1 or BRCA2 mutated cancers ( BRCA mut) have intrinsic sensitivity to PARP inhibitors due to deficiency in homologous recombination-mediated DNA…”
Get full text

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer by Hussain, Maha, Carducci, Michael A., Slovin, Susan, Cetnar, Jeremy, Qian, Jiang, McKeegan, Evelyn M., Refici-Buhr, Marion, Chyla, Brenda, Shepherd, Stacie P., Giranda, Vincent L., Alumkal, Joshi J.

“…Summary Androgen receptor-mediated transcription is directly coupled with the induction of DNA damage, and castration-resistant tumor cells exhibit increased…”
Get full text

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale by Isakoff, Steven J, Puhalla, Shannon, Domchek, Susan M, Friedlander, Michael, Kaufman, Bella, Robson, Mark, Telli, Melinda L, Diéras, Véronique, Han, Hyo Sook, Garber, Judy E, Johnson, Eric F, Maag, David, Qin, Qin, Giranda, Vincent L, Shepherd, Stacie P

“…Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in…”
Get full text

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC) by Mizugaki, Hidenori, Yamamoto, Noboru, Nokihara, Hiroshi, Fujiwara, Yutaka, Horinouchi, Hidehito, Kanda, Shintaro, Kitazono, Satoru, Yagishita, Shigehiro, Xiong, Hao, Qian, Jane, Hashiba, Hideyuki, Shepherd, Stacie P., Giranda, Vincent, Tamura, Tomohide

“…Abstact Introduction Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study…”
Get full text

The Drosophila Basic Helix-Loop-Helix Protein DIMMED Directly Activates PHM, a Gene Encoding a Neuropeptide-Amidating Enzyme by Park, Dongkook, Shafer, Orie T., Shepherd, Stacie P., Suh, Hyunsuk, Trigg, Jennifer S., Taghert, Paul H.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours by Berlin, Jordan, Ramanathan, Ramesh K., Strickler, John H., Subramaniam, Deepa S., Marshall, John, Kang, Yoon-Koo, Hetman, Robert, Dudley, Matthew W., Zeng, Jiewei, Nickner, Caroline, Xiong, Hao, Komarnitsky, Philip, Shepherd, Stacie Peacock, Hurwitz, Herbert, Lenz, Heinz-Josef

“…Background Veliparib is a potent poly(ADP-ribose) polymerase inhibitor. This phase 1 study aimed to establish the maximum tolerated dose (MTD) and recommended…”
Get full text

Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients by Nuthalapati, Silpa, Stodtmann, Sven, Shepherd, Stacie Peacock, Ratajczak, Christine K., Mensing, Sven, Menon, Rajeev, Xiong, Hao

“…Purpose Veliparib, a poly(ADP-ribose)-polymerase (PARP) 1 and 2 enzyme inhibitor, was administered at 120 mg twice daily (BID) for 7 days in a 21-day cycle…”
Get full text

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer by van der Biessen, Diane A. J., Gietema, Jourik A., de Jonge, Maja J. A., Desar, Ingrid M. E., den Hollander, Martha W., Dudley, Matthew, Dunbar, Martin, Hetman, Robert, Serpenti, Camille, Xiong, Hao, Mittapalli, Rajendar K., Timms, Kirsten M., Ansell, Peter, Ratajczak, Christine K., Shepherd, Stacie Peacock, van Herpen, Carla M. L.

“…Summary Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients…”
Get full text

Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion/rearrangement or wild-type (WT) FGFR2 by Shroff, Rachna T., Rearden, Jessica, Li, Ai, Moran, Susan, Shepherd, Stacie Peacock, Lamarca, Angela

“…Abstract only 4089 Background: CCA is a rare, heterogeneous malignancy with poor prognosis due to late onset of symptoms and relative resistance to available…”
Get full text

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol by Greenstein, Andrew, Munster, Pamela N., Sachdev, Jasgit C., Fleming, Gini F., Grauer, Andreas, Shepherd, Stacie Peacock

“…Abstract only 3091 Background: Cortisol, an endogenous glucocorticoid receptor (GR) agonist, controls a broad transcriptional program that affects T-cell…”
Get full text

Abstract 3623: Preclinical efficacy of the selective GR antagonist, CORT125134 by Hunt, Hazel, Belanoff, Joseph, Block, Thad, Shepherd, Stacie P.

“…The role of activation of the glucocorticoid receptor (GR) in the response of several solid tumor types to chemotherapy has been reported by several groups…”
Get full text

Abstract LB-130: Suppression of tumor immune activity in adrenocortical carcinoma with excess glucocorticoid by Greenstein, Andrew E., Habra, Mouhammed Amir, Mura, Marzena, Biernat, Paweł, Piatek, Marek J., Grauer, Andreas, Shepherd, Stacie Peacock

“…Introduction: Elevated glucocorticoid (GC) activity, while difficult to accurately quantify, has been implicated in the pathophysiology of multiple cancer…”
Get full text

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors by Munster, Pamela N, Greenstein, Andrew E, Fleming, Gini F, Borazanci, Erkut, Sharma, Manish R, Custodio, Joseph M, Tudor, Iulia Cristina, Pashova, Hristina I, Shepherd, Stacie Peacock, Grauer, Andreas, Sachdev, Jasgit C

“…Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential…”
Get full text

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer by Rodler, Eve T, Kurland, Brenda F, Griffin, Melissa, Gralow, Julie R, Porter, Peggy, Yeh, Rosa F, Gadi, Vijayakrishna K, Guenthoer, Jamie, Beumer, Jan H, Korde, Larissa, Strychor, Sandra, Kiesel, Brian F, Linden, Hannah M, Thompson, John A, Swisher, Elizabeth, Chai, Xiaoyu, Shepherd, Stacie, Giranda, Vincent, Specht, Jennifer M

“…Cisplatin is synergistic with vinorelbine and the PARP inhibitor veliparib, and has antineoplastic activity in triple-negative breast cancer (TNBC) and BRCA…”
Get full text

CTNI-76. EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394) IN RECURRENT, PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST) by de la Fuente, Macarena, Butowski, Nicholas, Taylor, Jennie, Yaeger, Rona, Tsai, Frank Yung-Chin, Janku, Filip, Allen, Carl, Ammakkanavar, Natraj, Michelson, Glenn, Jiang, Ping, Paz, Michael, Tussay-Lindenberg, Alexia, Wang, Kongming, Shepherd, Stacie Peacock, Kline, Irina, Sherman, Eric, Rodon, Jordi

“…Plixorafenib, a selective potent BRAFi, is uniquely designed to disrupt BRAF dimers and evade paradoxical MAPK pathway activation. Thus, it inhibits both V600…”
Get full text

A phase 1/2 study of relacorilant + nab-paclitaxel (nab-pac) in patients (pts) with solid tumors: The dose-finding phase by Munster, Pamela N., Sachdev, Jasgit C., Fleming, Gini F., Block, Thaddeus S., Shepherd, Stacie Peacock

“…Abstract only…”
Get full text

Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results by Sherman, Eric Jeffrey, De La Fuente, Macarena Ines, Yaeger, Rona, Tsai, Frank Yung-Chin, Janku, Filip, Butowski, Nicholas A., Allen, Carl E., Ammakkanavar, Natraj Reddy, Taylor, Jennie Webster, Samara, Emil, Mould, Diane R., Michelson, Glenn, Kline, Irina, Paz, Michael, Tussay-Lindenberg, Alexia, Wong, Kongming, Shepherd, Stacie Peacock, Jiang, Ping, Rodon Ahnert, Jordi

“…3106 Background: FORE8394 is a selective inhibitor of class 1 (V600) and 2 (activating non-V600) BRAF alterations that avoids paradoxical MAPK pathway…”
Get full text

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study by De La Fuente, Macarena Ines, Rodon Ahnert, Jordi, Yaeger, Rona, Tsai, Frank Yung-Chin, Janku, Filip, Butowski, Nicholas A., Allen, Carl E., Ammakkanavar, Natraj Reddy, Taylor, Jennie Webster, Michelson, Glenn, Kline, Irina, Paz, Michael, Tussay-Lindenberg, Alexia, Wong, Kongming, Shepherd, Stacie Peacock, Jiang, Ping, Sherman, Eric Jeffrey

“…3006 Background: FORE8394 is an investigational inhibitor (i) of class 1 (V600) and 2 (activating non-V600) BRAF-altered tumors. FORE8394 did not have…”
Get full text

TRLS-02. SAFETY AND EFFICACY OF BRAF INHIBITOR PLIXORAFENIB (FORE8394; PLX8394) IN CHILDREN AND ADULTS WITH RECURRENT, BRAF-ALTERED PRIMARY CENTRAL NERVOUS SYSTEM TUMORS (PCNST) by de la Fuente, Macarena, Butowski, Nicholas A, Taylor, Jennie, Yaeger, Rona, Tsai, Frank Y-C, Janku, Filip, Allen, Carl E, Ammakkanavar, Natraj, Michelson, Glenn, Jiang, Ping, Samara, Emil, Paz, Michael, Tussay-Lindenberg, Alexia, Wang, Kongming, Shepherd, Stacie P, Kline, Irina, Sherman, Eric, Rodon, Jordi

Get full text